166 related articles for article (PubMed ID: 31696729)
1. Is an analytical dose engine sufficient for intensity modulated proton therapy in lung cancer?
Teoh S; Fiorini F; George B; Vallis KA; Van den Heuvel F
Br J Radiol; 2020 Mar; 93(1107):20190583. PubMed ID: 31696729
[TBL] [Abstract][Full Text] [Related]
2. Radiobiological and dosimetric impact of RayStation pencil beam and Monte Carlo algorithms on intensity-modulated proton therapy breast cancer plans.
Rana S; Greco K; Samuel EJJ; Bennouna J
J Appl Clin Med Phys; 2019 Aug; 20(8):36-46. PubMed ID: 31343826
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive dosimetric study of Monte Carlo and pencil-beam algorithms on intensity-modulated proton therapy for breast cancer.
Liang X; Li Z; Zheng D; Bradley JA; Rutenberg M; Mendenhall N
J Appl Clin Med Phys; 2019 Jan; 20(1):128-136. PubMed ID: 30488548
[TBL] [Abstract][Full Text] [Related]
4. Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer.
Liu W; Schild SE; Chang JY; Liao Z; Chang YH; Wen Z; Shen J; Stoker JB; Ding X; Hu Y; Sahoo N; Herman MG; Vargas C; Keole S; Wong W; Bues M
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):523-533. PubMed ID: 26725727
[TBL] [Abstract][Full Text] [Related]
5. Impact of grid size on uniform scanning and IMPT plans in XiO treatment planning system for brain cancer.
Rana S; Zheng Y
J Appl Clin Med Phys; 2015 Sep; 16(5):447–456. PubMed ID: 26699310
[TBL] [Abstract][Full Text] [Related]
6. Technical Note: Treatment planning system (TPS) approximations matter - comparing intensity-modulated proton therapy (IMPT) plan quality and robustness between a commercial and an in-house developed TPS for nonsmall cell lung cancer (NSCLC).
Liu C; Yu NY; Shan J; Bhangoo RS; Daniels TB; Chiang JS; Ding X; Lara P; Patrick CL; Archuleta JP; DeWees T; Hu Y; Schild SE; Bues M; Sio TT; Liu W
Med Phys; 2019 Nov; 46(11):4755-4762. PubMed ID: 31498885
[TBL] [Abstract][Full Text] [Related]
7. Comparative photon and proton dosimetry for patients with mediastinal lymphoma in the era of Monte Carlo treatment planning and variable relative biological effectiveness.
Tseng YD; Maes SM; Kicska G; Sponsellor P; Traneus E; Wong T; Stewart RD; Saini J
Radiat Oncol; 2019 Dec; 14(1):243. PubMed ID: 31888769
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
9. Density overwrites of internal tumor volumes in intensity modulated proton therapy plans for mobile lung tumors.
Botas P; Grassberger C; Sharp G; Paganetti H
Phys Med Biol; 2018 Jan; 63(3):035023. PubMed ID: 29219119
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
Rana S; Cheng C; Zhao L; Park S; Larson G; Vargas C; Dunn M; Zheng Y
J Med Radiat Sci; 2017 Mar; 64(1):18-24. PubMed ID: 27741379
[TBL] [Abstract][Full Text] [Related]
11. Dose differences in intensity-modulated radiotherapy plans calculated with pencil beam and Monte Carlo for lung SBRT.
Liu H; Zhuang T; Stephans K; Videtic G; Raithel S; Djemil T; Xia P
J Appl Clin Med Phys; 2015 Nov; 16(6):91–99. PubMed ID: 26699560
[TBL] [Abstract][Full Text] [Related]
12. Clinical implementation of intensity modulated proton therapy for thoracic malignancies.
Chang JY; Li H; Zhu XR; Liao Z; Zhao L; Liu A; Li Y; Sahoo N; Poenisch F; Gomez DR; Wu R; Gillin M; Zhang X
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):809-18. PubMed ID: 25260491
[TBL] [Abstract][Full Text] [Related]
13. Organ sparing potential and inter-fraction robustness of adaptive intensity modulated proton therapy for lung cancer.
van der Laan HP; Anakotta RM; Korevaar EW; Dieters M; Ubbels JF; Wijsman R; Sijtsema NM; Both S; Langendijk JA; Muijs CT; Knopf AC
Acta Oncol; 2019 Dec; 58(12):1775-1782. PubMed ID: 31556764
[No Abstract] [Full Text] [Related]
14. Dosimetric comparison of distal esophageal carcinoma plans for patients treated with small-spot intensity-modulated proton versus volumetric-modulated arc therapies.
Liu C; Bhangoo RS; Sio TT; Yu NY; Shan J; Chiang JS; Ding JX; Rule WG; Korte S; Lara P; Ding X; Bues M; Hu Y; DeWees T; Ashman JB; Liu W
J Appl Clin Med Phys; 2019 Jul; 20(7):15-27. PubMed ID: 31112371
[TBL] [Abstract][Full Text] [Related]
15. Impact of proton dose calculation algorithms on the interplay effect in PBS proton based SBRT lung plans.
Rana S; Rosenfeld AB
Biomed Phys Eng Express; 2021 May; 7(4):. PubMed ID: 34029212
[No Abstract] [Full Text] [Related]
16. Difference in LET-based biological doses between IMPT optimization techniques: Robust and PTV-based optimizations.
Hirayama S; Matsuura T; Yasuda K; Takao S; Fujii T; Miyamoto N; Umegaki K; Shimizu S
J Appl Clin Med Phys; 2020 Apr; 21(4):42-50. PubMed ID: 32150329
[TBL] [Abstract][Full Text] [Related]
17. Transitioning from measurement-based to combined patient-specific quality assurance for intensity-modulated proton therapy.
Chen M; Yepes P; Hojo Y; Poenisch F; Li Y; Chen J; Xu C; He X; Gunn GB; Frank SJ; Sahoo N; Li H; Zhu XR; Zhang X
Br J Radiol; 2020 Mar; 93(1107):20190669. PubMed ID: 31799859
[TBL] [Abstract][Full Text] [Related]
18. A comparison of two pencil beam scanning treatment planning systems for proton therapy.
Langner UW; Mundis M; Strauss D; Zhu M; Mossahebi S
J Appl Clin Med Phys; 2018 Jan; 19(1):156-163. PubMed ID: 29205763
[TBL] [Abstract][Full Text] [Related]
19. Assessment of robustness against setup uncertainties using probabilistic scenarios in lung cancer: a comparison of proton with photon therapy.
Teoh S; George B; Fiorini F; Vallis KA; Van den Heuvel F
Br J Radiol; 2020 Mar; 93(1107):20190584. PubMed ID: 31977241
[TBL] [Abstract][Full Text] [Related]
20. Improve dosimetric outcome in stage III non-small-cell lung cancer treatment using spot-scanning proton arc (SPArc) therapy.
Li X; Kabolizadeh P; Yan D; Qin A; Zhou J; Hong Y; Guerrero T; Grills I; Stevens C; Ding X
Radiat Oncol; 2018 Feb; 13(1):35. PubMed ID: 29486782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
